Rebekah Jordan shares her view from the seat at the Editor’s Desk on what impact the post-Brexit era might have on the UK process of medicine approvals and how external pharma manufacturers may respond.
The UK’s future role in R&D within the life sciences sector currently stands on unstable ground. On the back of the Brexit vote, the UK left the European Medicines Agency (EMA) – the EU drugs regulator – leaving all future medicine to be vetted and approved by the UK’s equivalent; Medicine and Healthcare products Regulatory Agency (MHRA).